BioSpace News Archive

Santhera Pharmaceuticals announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on orphan drug designation for POL6014 in the treatment of cystic fibrosis (CF), a rare pulmonary disease affecting around 35,000 people in the European Union.

Karolinska Development’s portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health.

GeoVax Labs, Inc. today is observing National Latinx AIDS Awareness Day, a time to focus on the continuing and disproportionate impact of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) on Hispanics/Latinos in the United States.

Sysmex Inostics is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to complement standard-of-care management of patients with advanced melanoma.

Preparation of a Phase II program for THN101 in patients with neuropathic pain

Proteostasis Therapeutics announced positive preliminary data from its ongoing Phase I clinical trial of PTI-808 and PTI-801 in cystic fibrosis (CF). Despite it being an early-stage trial and preliminary data, company shares exploded upward by 301 percent, with more than 44 million shares trading hands.

The management board of Probiodrug AG notifies today in accordance with Section 92 (1) of the German Stock Corporation Act that according to its best judgment a cumulative loss of more than half of the nominal share capital of the company must be assumed.

DeltaTrak® today announced it will feature its FlashLink -80°C In-Transit Data Logger and FlashTrak Telematics Out-Time Solution at CAMX Composites and Advanced Materials Expo (Booth BB55), at the Kay Bailey Hutchison Convention Center in Dallas Texas, October 16 to 18, 2018.

Customer receipts for the first quarter of FY2019 at $2.01 million, up 100% from the same period in FY2018 ($1.01 million)

SAPHIR trial data published in Alzheimer’s Research & Therapy